Cardiff Oncology shareholders reject advisory vote on executive compensation at 2022 annual meeting

Cardiff Oncology, Inc.

Corrected voting results show say-on-pay failed: 7.93M For, 7.36M Against, 2.02M Abstain, 12.06M broker non-vote.
All seven director nominees elected; BDO USA ratified as auditor; amendment to 2021 Omnibus Equity Plan approved.
Amendment filed to correct original 8-K error in Proposal 4 (advisory vote on executive compensation) results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.